您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 眼科药物->治疗青光眼药物
处方药:处方药
包装规格: 2.5毫升/瓶 5瓶/盒
计价单位:
   
生产厂家中文参考译名:
默克
生产厂家英文名:
Merck
该药品相关信息网址1:
http://www.igenericdrugs.com/gd.cgi?notran=1&s=Tafluprost+&search=SEARCH
原产地英文商品名:
ZIOPTAN 0.0015% 2.5ml 5bottles
原产地英文药品名:
Tafluprost
中文参考商品译名:
ZIOPTAN 0.0015% 2.5毫升/瓶 5瓶/盒
中文参考药品译名:
他氟前列腺素
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
ocular hypertension
英文适应病症2:
primary open-angle glaucoma
临床试验期:
完成
中文适应病症参考翻译1:
高眼压症
中文适应病症参考翻译2:
原发性开角型青光眼
药品信息:
ZIOPTAN (tafluprost/他氟前列腺素 眼溶液) 0.0015% 美国初始批准:2012年 适应证和用途 ZIOPTAN(tafluprost眼溶液) 0.0015% 是一种前列腺素类似物适用于开角型青光眼或眼高压患者中减低升高的眼内压。 剂量和给药方法 在患眼(s)中一滴每天1次在傍晚。 剂型和规格 含tafluprost眼溶液0.015 mg/mL。 禁忌证 无。 警告和注意事项 (1)色素沉着 可能发生虹膜,眼周组织(眼睑)和眼睫毛色素沉着。虹膜色素沉着很可能是永久性的。(5.1) (2)睫毛变化 对眼睫毛包括长度,厚度增加逐渐改变和睫毛数. Usually reversible. (5.2) 不良反应 (1) 最常见眼不良反应是结膜充血(范围4% – 20%)。 (6.1) 为报告怀疑不良反应,联系Merck Sharp & Dohme Corp.,,Merck & Co., Inc., 子公司电话1-877888-4231或FDA电话-800-FDA-1088或 www.fda.gov/medwatch. 特殊人群中使用 (1)建议儿童患者不要使用因为长期慢性使用后色素沉着增加相关的潜在的安全性关注。 Tafluprost - Reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Data regarding concomitant use of Tafluprost ophthalmic solution 0.0015% with other topical ophthalmic drug products to lower intraocular pressure is limited. Reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. These highlights do not include all the information needed to use ZIOPTAN (tafluprost ophthalmic solution) 0.0015% safely and effectively. See full prescribing information for ZIOPTAN. ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015% Initial U.S. Approval: 2012 ----------------------------INDICATIONS AND USAGE ---------------------------• ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.(1) -----------------------DOSAGE AND ADMINISTRATION-----------------------• One drop in the affected eye(s) once daily in the evening. (2) ---------------------DOSAGE FORMS AND STRENGTHS --------------------• Ophthalmic solution containing tafluprost 0.015 mg/mL. (3) -------------------------------CONTRAINDICATIONS ------------------------------• None. (4) ------------------------WARNINGS AND PRECAUTIONS-----------------------• Pigmentation Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. (5.1) • Eyelash Changes Gradual changes to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2) ------------------------------ADVERSE REACTIONS------------------------------• Most common ocular adverse reaction is conjunctival hyperemia (range 4% – 20%). (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. -----------------------USE IN SPECIFIC POPULATIONS ----------------------• Use in pediatric patients is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
更新日期: 2013-08-15
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com